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Abstract:  High-altitude  pulmonary  hypertension  (HAPH)  affects  individuals  residing  at  altitudes  of  2,500  meters  and  higher.
Numerous pathogenic variables play a role in disease inception and progression and include low oxygen concentration in inspired air,
vasculopathy,  and metabolic  abnormalities.  Since HAPH affects  only some people  living at  high altitude genetic  factors  play a
significant role in its pathogenesis.
The clinical presentation of HAPH is nonspecific and includes fatigue, shortness of breath, cognitive deficits, cough, and in advanced
cases  hepatosplenomegaly  and  overt  right-sided  heart  failure.  A  thorough  history  is  important  and  should  include  a  search  for
additional risk factors for lung disease and pulmonary hypertension (PH) such as smoking, indoor air pollution, left-sided cardiac
disease and sleep disordered breathing. Twelve-lead electrocardiogram, chest X-ray and echocardiography can be used as screening
tools. A definitive diagnosis should be made with right-sided heart catheterization using a modified mean pulmonary artery pressure
of at least 30 mm Hg, differing from the 25 mm Hg used for other types of PH.
Treatment of HAPH includes descent to a lower altitude whenever possible, oxygen therapy and the use of medications such as
endothelin receptor antagonists, phosphodiesterase 5 blockers, fasudil and acetazolamide. Some recent evidence suggests that iron
supplementation may also be beneficial. However, it is important to note that the scientific literature lacks long-term randomized
controlled data on the pharmacologic treatment of HAPH. Thus, an individualized approach to treatment and informing the patients
regarding the benefits and risks of the selected treatment regimen are essential.
Keywords: Altitude physiology, cardiac failure, epidemiology, treatment.
1. INTRODUCTION
Pulmonary hypertension (PH) is a group of disorders generally characterized by a mean pulmonary arterial pressure
≥25 mm Hg on right heart catheterization [1 - 3]. The most recent PH classification includes five main groups shown in
Table 1. The association of PH with other medical disorders has a worse prognosis. For example, the presence of PH in
chronic obstructive pulmonary disease (COPD) is linked to greater morbidity and mortality [4].
High-altitude  pulmonary  hypertension  (HAPH)  is  included  in  the  third  of  these  groups  according  to  the  latest
classification of PH [1]. It is known that more than 140 million people permanently reside at high altitudes and more
than 40 million people visit these areas for recreational and other reasons [6]. Indeed, some lowland individuals develop
acute mountain sickness every year due to rapid ascent and the decrease in partial pressure of oxygen [7].
The goal of this article is to review our current understanding of HAPH. First, the pathogenesis of HAPH will be
discussed, including the role of hypoxia, genetics and other factors that play a role in the development of this disease.
Second,  the  epidemiology  of  HAPH  will  be  reviewed.  Third,  we  will  discuss  the  clinical  presentation  and
symptomatology of HAPH. Fourth, the diagnostic work-up of patients with HAPH will be reviewed. Finally, we will
* Address correspondence to this author at the Case Western Reserve University, Division of Pulmonary, Critical Care and Sleep Medicine, 11100
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discuss the therapeutic options and management of patients with HAPH.
2. SEARCH STRATEGY
We  searched  PubMed/Medline,  Scopus,  Embase  and  Web  of  Science  for  articles  focused  on  high-altitude
pulmonary  hypertension  published  from  1950  to  January  2015.  The  search  terms  were:  high-altitude  pulmonary
hypertension,  chronic  mountain  sickness,  mountain  sickness,  cardiac  mountain  sickness,  Monge  disease  and  the
combination of these. The reference lists of the identified articles were further screened for potentially relevant articles
that may have been overlooked by the electronic search. The search methodology was adapted from the scientific search
guidelines published in 2011 [5].
3. PATHOGENESIS OF NAPH
On a molecular level,  hypoxia alters the activity of ion channels.  More specifically,  hypoxia downregulates the
activity of potassium channels and modulates the activity of calcium channels, leading to an increase in intracellular
calcium [15]. These changes in turn augment smooth muscle cell proliferation, reduce the apoptosis of smooth muscle
cells and alter the activity of pulmonary endothelial cells, favoring the production of vasoconstrictive substances such as
endothelin, thromboxane A2 and others [16 - 20].
Nitric oxide (NO) is a key vasodilator of the pulmonary circulation and its decreased availability is believed to play
a major role in the development of PH [21].  It  has been shown by Anand that inhaled NO can mitigate pulmonary
vascular  resistance  in  patients  with  acute  mountain  sickness  in  the  form  of  high-altitude  pulmonary  edema  [22].
Furthermore, certain medications used in the management of PH target the bioavailability of NO as will be discussed in
the treatment section. It is interesting to note here that some populations living at high altitude for a long time have a
lower  prevalence  of  HAPH  and  other  high-altitude-related  diseases.  For  example,  native  Tibetans  have  higher
pulmonary NO concentrations than other populations which might explain a low prevalence of HAPH [23 - 27]. In a
recent  study,  Siques  et  al.  demonstrated  that  continuous  hypoxia  results  in  both  the  decreased  synthesis  and
bioavailability  of  NO  [28].  Furthermore,  α1-A680T  Variant  in  GUCY1A3  (guanylate  cyclase)  may  be  protective
against the development of HAPH through increase in cellular NO [29].
Scientific data suggest  that  genetics plays a role in the susceptibility to HAPH. For example,  the Sherpa ethnic
group  living  in  Nepal  has  a  Glu  298Asp  polymorphism of  the  G allele  of  the  NO synthase  gene  [30].  The  role  of
angiotensin converting enzyme (ACE) polymorphisms has also been studied. Aldashev et al. studied ACE genotyping
among 212 adult Kyrgyz lowlanders and 78 adult male highlanders [31, 32]. These researchers showed that the I allele
of  ACE was  associated  with  the  presence  of  HAPH.  The  results  of  this  study  were  interesting  since  the  I  allele  is
associated with a reduced level of ACE activity, which should have a vasodilatory effect on the pulmonary circulation
due to the reduced availability of angiotensin II.  These researchers speculated that  the I  allele of ACE may endure
greater  physical  endurance,  which  in  turn  may  lead  to  augmented  cardiac  output  and  pulmonary  artery  pressure;
alternatively,  the  association  between  ACE and  HAPH could  be  explained  by  the  proximity  of  the  ACE gene  to  a
HAPH susceptibility locus. Finally, the susceptibility of the Kyrgyz population to HAPH in their study was associated
with hyperreactivity to acute hypoxia. For a more detailed discussion on genetic susceptibility to HAPH and other high-
altitude diseases the reader is referred to a well-written review article [30].
It is important to bear in mind that other factors may contribute to the development of elevated PH in people living
at  high  altitude.  For  example,  premenopausal  women  have  a  lower  burden  of  HAPH  compared  to  men  [33].  This
observation may be explained by the stimulatory effects of female sex hormones on ventilatory drive. Indeed, the native
Tibetan population has augmented ventilation, which is believed to be protective against the development of HAPH.
Other factors that can detrimentally affect pulmonary artery pressure and pulmonary health include sleep disordered
It is well known that high altitude areas have a lower oxygen concentration compared to lowland territories [8].
Indeed, research data show that a hypoxic stimulus leads to pulmonary vasoconstriction and an increase in pulmonary
vascular resistance [9]. This physiologic response is an important phenomenon aiming to reduce the perfusion of poorly
ventilated lung areas and redistribute more blood flow to better-oxygenated zones. Hypoxic stimuli also lead to vascular
remodeling at the level of small pulmonary arteries and veins, which are normally devoid of smooth muscle cells [9,
10]. However, hypoxia appears to stimulate the proliferation of smooth muscle cells from the local myofibroblasts [9 -
14].  It  is  interesting to note that these vascular changes persist  even after return to normoxia,  suggesting that these
morphologic changes play an important role in the perpetuation of elevated pulmonary artery pressure.
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breathing [34, 35], indoor air pollution [36], smoking [37], iron deficiency [38] and erythrocytosis with increased blood
viscosity [39].
In summary, hypoxic stimuli lead to an increase in pulmonary arterial vasoconstriction and vascular remodeling
through the alteration of ion channel activity. Vascular remodeling includes the proliferation of smooth muscle cells in
pulmonary vessels that are normally devoid of them and decreased apoptosis of these cells. Moreover, it also modulates
the  biochemical  activity  of  pulmonary  endothelium  with  a  shift  towards  the  production  of  substances  such  as
endothelin-1. The role of genetic predisposition seems to be essential for the development of disease, but is not entirely
understood at this time. Other factors and comorbidities may also play some role in selected circumstances.
4. EPIDEMIOLOGY OF HAPH
As mentioned above, about 140 million people permanently live at high altitude, which is generally defined as being
at least 2500 meters above sea level [6, 7]. Current scientific data on the prevalence of HAPH are scarce. Nevertheless,
several studies have attempted to investigate the burden of HAPH in at-risk populations.
Aldashev et al. screened 741 high-altitude residents via electrocardiogram (ECG) for the presence of ECG findings
of right heart hypertrophy and involvement [32]. They demonstrated that 23% of men and 6% of women had ECG
evidence of right heart involvement. Eleven patients further underwent right heart catheterization, and a resting mean
pulmonary artery pressure >25 mm Hg was found in eight of these. In a later study, Aldashev et al. screened 689 high-
altitude residents (313 men) with ECG for the presence of right ventricular involvement [40]. The ECG criteria for right
ventricular hypertrophy were met in 188 subjects (27%) of whom 113 were men. Later, right cardiac catheterization
was performed in 44 individuals with ECG evidence of right ventricular hypertrophy. It was found that 29 patients (25
men) who underwent right cardiac catheterization had a mean pulmonary artery pressure >25 mm Hg. It was estimated
that the prevalence of HAPH was 18% in their study. However, it is essential to bear in mind that the sensitivity of ECG
for the detection of right ventricular enlargement as a marker of HAPH is quite low, at around 20% [41].
Studies from South America have demonstrated a prevalence of HAPH ranging from 5 to 18% [9, 42]. Thus, based
on current scientific literature we can assume that the rough prevalence of HAPH ranges from 5 to 18% in populations
at risk and is more common in men. In a recent study by Negi et al. demonstrated HAPH prevalence of 3.23% among
natives of Spiti Valley, India [43].
Table 1. Classification of PH.
Group Etiologies
Group 1. Idiopathic, heritable, connective tissue disease,
HIV infection, portopulmonary hypertension, congenital heart disease, drug/toxin induced,
chronic hemolytic anemia, schistosomiasis, persistent PH of the newborn, pulmonary
venoocclusive disease and pulmonary capillary hemangiomatosis.
Group 2. PH owing to left heart disease Systolic and diastolic dysfunction, mitral and aortic valve diseases
Group 3. Pulmonary hypertension owing to lung
diseases and/or hypoxia
High-altitude pulmonary hypertension, chronic obstructive pulmonary disease, interstitial lung
disease, sleep disordered breathing etc.
Group 4. Chronic Thromboembolic pulmonary
hypertension
Unresolvedfibrin thromboembolization to the pulmonary arteries.
Group 5. Pulmonary hypertension with unclear
multifactorial mechanisms
Myeloproliferative disorders, splenectomy,
pulmonary vasculitis, neurofibromatosis, thyroid disorders etc.
5. CLINICAL PRESENTATION OF HAPH
The clinical  presentation of  PH is  nonspecific,  and patients  typically present  with exertional  symptoms such as
progressive  dyspnea,  chest  pain/discomfort,  and  in  advanced  cases  dizziness  and  syncope  [1].  Cough,  hemoptysis,
fatigue, and lower extremity pitting edema are also common presenting features. It is also important to bear in mind that
patients with HAPH may have other non-specific symptoms such as fatigue, headaches and cognitive impairment [44].
Physical  examination  can  be  very  helpful  in  signaling  problems  in  the  pulmonary  circulation.  An  early
manifestation is an increase in the intensity of the second pulmonic sound (P2), but as the disease progresses, the right
ventricle enlarges so that an impulse or heave can be appreciated in the left lower sternal border. The tricuspid valve
becomes more incompetent as the RV enlarges, and a holosystolic murmur indicative of tricuspid regurgitation becomes
audible  in  the  left  and  right  lower  sternal  borders.  The  onset  of  RV  failure  leads  to  jugular  venous  stenosis,
hepatojugular reflux, peripheral edema, liver and spleen enlargement as well as ascites [2]. These are not specific for
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isolated  right  ventricular  failure  and  are  also  commonly  seen  with  left  ventricular  dysfunction.  During  physical
examination, it is essential to search for signs of systemic autoimmune diseases (particularly systemic sclerosis) such as
joint pains, skin thickening, malar rash, telangiectasia, and Raynaud’s phenomenon in order to detect other potential
etiologies for elevated pulmonary artery pressure [1, 44, 45].
6. DIAGNOSTIC WORK-UP OF HAPH
It  is important to consider the diagnosis of PH in patients with shortness of breath, syncope, fatigue, peripheral
edema, abdominal discomfort and hepatomegaly. The symptoms and signs mentioned above are nonspecific for PH.
Physical examination is essential and should focus on the signs presented in the previous section. It is also important to
emphasize that history and physical examination should seek alternative or additional risk factors for PH in people
residing  at  high  altitudes  such  as  smoking,  presence  of  sleep  disordered  breathing,  autoimmune  disease  etc.
Furthermore, the diagnosis of HAPH requires residence at an altitude of at least 2500 meters above sea level [44].
Several instrumental tests can be of help in evaluating patients with the aforementioned complaints and physical
signs. Twelve-lead electrocardiogram (ECG) is a relatively inexpensive diagnostic tool that can also assist in detecting
other potential explanations for the patients’ presentation. ECG may reveal “p” pulmonale consisting of tall P waves
(≥3  mm)  in  the  inferior  leads,  right  axis  deviation,  or  right  bundle  branch  block  and  R  to  S  ratio  >  1  in  lead  V1,
indicative  of  right  ventricular  hypertrophy.  ST  depression  in  leads  V1  to  V3  suggests  right  ventricular  strain  in
combination with other findings. However, these findings were shown to have limited sensitivity for diagnosing PH,
especially in patients with mild PH [41, 46], and are of limited prognostic value [46].
Echocardiography in patients with PH may show an increase in pulmonary artery pressure, as well as enlargement
of right atrium and ventricle. It also provides important information on left heart function. Despite having much greater
sensitivity and specificity for PH than the ECG and CXR, the cardiac echo may under or overestimate the degree of
pulmonary artery pressure [47]. It is important to note that ECG combined with echocardiographic assessment may be
used for the screening of HAPH given their noninvasive nature, as shown by Kojonazarov et al. in a study of Kyrgyz
highlanders [48].
Chest X-ray (CXR) is an important test for evaluating patients presenting with shortness of breath, chest pain, and
other respiratory-related symptoms, as PH is one of many conditions that can present with these symptoms (such as
pulmonary hyperinflation secondary to chronic obstructive pulmonary disease). In PH, the CXR may be completely
normal but is apt to show evidence of RV or PA enlargement and prominence of pulmonary vasculature in advanced
cases. However, the utility of CXR in diagnosing PH is limited due to its lack of sensitivity.
Pulmonary  function  tests  (PFT)  are  important  mostly  to  exclude  other  potential  causes  of  PH (such  as  chronic
obstructive pulmonary disease and interstitial lung diseases) [2, 3].
Nuclear  ventilation  perfusion  (V/Q)  scans  are  typically  performed in  order  to  exclude  chronic  thromboembolic
pulmonary hypertension (CTEPH) [2]. V/Q scans can show large ventilation perfusion mismatch suggestive of CTEPH.
It  is  important  to  be  aware  of  the  limitations  of  V/Q  scans,  which  include  decreased  sensitivity  and  specificity  in
patients  with  underlying  pulmonary  disease,  and  overall  low  specificity,  since  other  pathologies  may  give  similar
findings. Due to the limited specificity of V/Q scans, patients with positive findings typically undergo further imaging
studies to better quantify disease severity and exclude alternative diagnoses. As long as renal function is acceptable,
computed tomography-pulmonary angiography (CT-PA) is usually performed next in cases of suggestive V/Q scans,
since it has greater specificity than V/Q scans and can help exclude other diseases.
Pulmonary angiography (PA) and right heart catheterization is the mainstay of diagnosis confirmation and disease
prognostication. Measurement of mPAP at rest and mean pulmonary capillary wedge pressure (mPCWP) is performed
during right heart catheterization. PH is diagnosed when mPAP during rest ≥25 mmHg and mPCWP < 15 mmHg [1].
However, it is important to bear in mind that mPAP of >30 mm Hg and systolic PAP of >50 mm Hg should be used as
diagnostic criteria for HPAH [44]. The measurement of mPCWP is important since PH secondary to left heart disease is
essentially  ruled  out  at  values  less  than  15  mmHg  [1].  However,  mPCWP  >  15  may  be  secondary  to  dilation  of
pulmonary arteries and in such cases, it  is essential to measure left  ventricular end diastolic pressure. As described
earlier it is important to seek additional or alternative etiologies for elevated PAP in patients residing at high altitudes
since their presence excludes HAPH [44]. Furthermore, management of elevated PAP can differ from that of HAPH
itself as, for example, in the presence of mitral stenosis complicated by the development of PH.
In  summary,  it  is  essential  to  exclude  PH  secondary  to  left-sided  cardiac  disease,  PH  secondary  to  pulmonary
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disease, CTEPH, and other etiologies in appropriate clinical scenarios (such as portopulmonary hypertension and PH
secondary  to  sickle  cell  disease)  before  attributing  the  etiology  to  HPAH.  Furthermore,  right  heart  catheterization
should be performed at the altitude of residence, which is not always technically feasible. It is important to bear in mind
that diagnosis of HAPH requires mPAP of more than 30 mm Hg or systolic PAP of more than 50 mm Hg on right heart
catheterization [44].
7. TREATMENT OF HAPH
The scientific literature on the topic of management of HAPH is limited to a few randomized trials. It is important to
bear in mind that whenever possible it is reasonable to advise migration to lower altitudes. Sime et al. showed that high-
altitude residents showed normalization of mPAP after 2 years of living at low altitude [49]. It is interesting to note that
mPAP increased upon return to high altitude. Fried and Reid also demonstrated this phenomenon following two days of
descent to low altitude [50].
It is well known that NO is an essential bioactive chemical and is implicated in the pathogenesis of various forms of
PH,  including  HAPH.  Phosphodiesterase  type  5  (PDE-5)  isoenzyme  is  a  known  factor  that  degrades  NO  in  vivo.
Medications inhibiting PDE-5 such as sildenafil, tadalafil and others have been shown to be beneficial for patients with
HAPH. Richalet et al. studied 12 male patients and exposed them to an altitude of 4, 350 meters for 6 days [51]. The
subjects  were  randomly  assigned  to  placebo  and  sildenafil.  They  showed that  subjects  assigned  to  sildenafil  had  a
greater partial pressure of oxygen, a lower difference in oxygen levels between the alveolar and arterial compartments
and greater maximal oxygen consumption. In another study, Aldashev et al. randomized 22 individuals with HAPH to
placebo and sildenafil for 12 weeks in a double-blind fashion [40]. This group showed that sildenafil reduced mPAP,
improved physical endurance and had a minimal effect on systemic blood pressure. In a recent meta-analysis Xu et al.
concluded that sildenafil reduces mPAP, but has no major effects on oxygen saturation and heart rate [52].
Endothelin receptor blockers such as bosentan are used successfully in the management of PAH. In a recent study
Seheult et al. studied eight patients who were exposed to an altitude of 3,800 meters and randomized them to bosentan
and placebo in a double-blind methodology [53]. Bosentan was started 5 days prior to ascent. Unfortunately, bosentan
was not shown to reduce mPAP or increase exercise capacity, and actually worsened oxygen saturation. However, a
later study by Kojonazarov et al., who enrolled high-altitude residents with HAPH, showed that patients with HAPH
have higher levels of endothelin as well as that bosentan therapy reduced pulmonary artery systolic pressure more than
oxygen administration [54].
Acetazolamide is a carbonic anhydrase inhibitor and weak diuretic that is a key agent used in the prevention of high-
altitude  sickness  [55].  In  a  recent  study,  Richalet  et  al.  studied  the  utility  of  acetazolamide  in  the  management  of
chronic altitude sickness [56]. In their study acetazolamide increased nocturnal oxygen saturation and led to a reduction
in secondary polycythemia. Moreover, it was shown that acetazolamide reduced pulmonary vascular resistance. Given
its  minimal  side  effect  profile  acetazolamide  can  be  used  in  patients  with  chronic  mountain  sickness  and  possibly
HAPH.
Smith et al. aimed to study an interesting hypothesis on iron availability and HAPH [57]. These researchers enrolled
two groups of individuals: first 22 healthy subjects normally residing at sea level were exposed to an altitude of 4,340
meters and received intravenous iron sucrose on the third day of stay at high altitude. The second group included 11
men  usually  residing  at  high  altitude  who  had  chronic  mountain  sickness  and  who  underwent  staged  isovolemic
venesection of 2 liters of blood. It is interesting to note that iron infusion was associated with reduced pulmonary artery
systolic pressure in sea-level residents, whereas venesection was associated with increased pulmonary artery systolic
pressure in high-altitude residents. However, iron infusion did not improve pulmonary artery systolic pressure in their
study.  The  researchers  concluded  that  the  role  of  iron  may  be  more  complex  than  believed  in  the  pathogenesis  of
chronic mountain sickness and HAPH, and avoidance of iron deficiency should be an aim in patients with HAPH.
Kojonazarov et al. studied a Rho A/Rho kinase inhibitor fasudil in a double-blind randomized study involving 19
patients with HAPH [58]. It was shown that fasudil beneficially decreased pulmonary artery systolic pressure compared
to placebo, was well tolerated and had no effects on systemic blood pressure.
In conclusion, no long-term data are available on the management of HAPH. Ideally, all patients with HAPH should
be advised to descend to a lower altitude. The limitations of the data on pharmacological correction of HAPH should be
discussed with every patient with HAPH and an informed decision should be reached. The cost  of the medications
should be kept in mind since a significant percent of high-altitude residents reside in low-income countries and hence,
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may not be able to afford them.
CONCLUSION
HAPH  is  a  common  disease  afflicting  individuals  living  at  high  altitudes  yet  this  is  an  understudied  disorder.
Studies should further elaborate the pathobiology of this condition since many people residing at high altitude do not
have this disorder. A better understanding of the disease pathogenesis may translate into newer therapeutic targets and
treatments for this condition.
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